BARONE, STEFANIA
 Distribuzione geografica
Continente #
EU - Europa 94
NA - Nord America 84
AS - Asia 53
AF - Africa 2
OC - Oceania 1
Totale 234
Nazione #
US - Stati Uniti d'America 84
IT - Italia 63
SG - Singapore 49
SE - Svezia 6
EE - Estonia 4
FI - Finlandia 4
GB - Regno Unito 4
DE - Germania 3
NL - Olanda 3
ES - Italia 2
FR - Francia 2
NG - Nigeria 2
AT - Austria 1
AU - Australia 1
CN - Cina 1
CZ - Repubblica Ceca 1
HK - Hong Kong 1
IN - India 1
PK - Pakistan 1
RU - Federazione Russa 1
Totale 234
Città #
Singapore 18
Santa Clara 13
Chandler 11
Milan 9
Rome 5
Boardman 4
Chicago 4
Florence 4
Lawrence 4
London 4
Misterbianco 4
Princeton 4
Cittanova 3
Montecorice 3
San Nicola Manfredi 3
Abuja 2
Amantea 2
Ashburn 2
Aversa 2
Bologna 2
Borgia 2
Casoria 2
Catanzaro 2
Helsinki 2
Lamezia Terme 2
Madrid 2
Morciano di Leuca 2
The Dalles 2
West Jordan 2
Wilmington 2
Augusta 1
Bari 1
Bitonto 1
Bra 1
Caserta 1
Duncan 1
Düsseldorf 1
Frontenard 1
Hong Kong 1
Karachi 1
Munich 1
Naples 1
Norwalk 1
Olomouc 1
Perth 1
San Mateo 1
Vienna 1
Totale 140
Nome #
Hepatic Encephalopathy by Manganese Deposition: A Case Report and a Review of Literature 31
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables 29
Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab 27
Listeria infection after treatment with alemtuzumab: A case report and literature review. would antibiotic prophylaxis be considered? 26
Headache due to intracranial hypertension at the time of first manifestation of multiple sclerosis 25
Opicapone-induced reversible myopathy in a patient with advanced Parkinson’s disease and familial hyperCKemia 25
The one-and-a-half syndrome: a distinctive clinical finding in a patient with multiple sclerosis 24
Two cases of unilateral wasting and weakness of distal upper limb: Similar onset and different diagnosis in young patients 24
Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic 15
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 11
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 8
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 5
Correction to: Daytime sleepiness and sleep quality in Charcot–Marie–Tooth disease 4
Totale 254
Categoria #
all - tutte 3.001
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.001


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 2 0 0 0 6 0 6 0 0
2021/202212 0 0 0 4 3 0 0 1 3 1 0 0
2022/202363 8 4 2 3 2 4 1 1 2 4 11 21
2023/202461 11 10 3 5 2 7 13 3 0 2 0 5
2024/2025104 15 1 0 6 16 17 8 8 27 6 0 0
Totale 254